1092522-02-5

Basic information

• Product Name: (4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester
• Synonyms: (4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester;tert-Butyl (4-aminophenyl)(methyl)carbamate
• CAS NO: 1092522-02-5
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.29
• Mol File: 1092522-02-5.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: (4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester(1092522-02-5)
• EPA Substance Registry System: (4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester(1092522-02-5)

Safety Data

• Hazardous Substances Data: 1092522-02-5(Hazardous Substances Data)

Usage

General Description

(4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester, also known as carbanilic acid tert-butyl ester, is a chemical compound with the molecular formula C12H16N2O2. It is a carbamic acid ester derivative with a tert-butyl substituent. (4-Amino-phenyl)-methyl-carbamic acid tert-butyl ester is mainly used as an intermediate in the production of pharmaceuticals and other organic compounds. It is categorized as a pesticide, a chemical intermediate, and an agrochemical. The compound has various industrial applications, including use in the synthesis of active pharmaceutical ingredients and intermediates. It is important to handle this compound with proper safety precautions due to its potential health hazards and environmental impact.

Upstream product

• 100-01-6 4-nitro-aniline 
• 50-00-0 formaldehyd 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 18437-63-3 tert-butyl N-(4-nitrophenyl)carbamate 
• 100-15-2 N-methyl(p-nitroaniline) 
• 24424-99-5 di-tert-butyl dicarbonate 
• 474020-88-7 tert-butyl N-methyl-N-(4-nitrophenyl)carbamate 

Downstream Products

• 1092522-00-3 tert-butyl 4-(p-fluorophenylsulfonamido)phenyl-(methyl)carbamate 
• 1259030-05-1 N-methyl-N-[4-(3-phenylureido)phenyl]carbamic acid tert-butyl ester 
• 1448444-79-8 tert-butyl 4-(6-(dibenzylamino)-5-nitropyrimidin-4-ylamino)phenyl(methyl)carbamate 
• 656247-17-5 nintedanib 
• 1987887-92-2 methyl (Z)-3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate 

Relevant articles and documents

Targeting metal-Aβ aggregates with bifunctional radioligand [11C]L2-b and a fluorine-18 analogue [18F]FL2-b

Interest in quantifying metal-Aβ species in vivo led to the synthesis and evaluation of [11C]L2-b and [18F]FL2-b as radiopharmaceuticals for studying the metallobiology of Alzheimer's disease (AD) using positron emission tomography (PET) imaging. [11C]L2-b was synthesized in 3.6% radiochemical yield (nondecay corrected, n = 3), >95% radiochemical purity, from the corresponding desmethyl precursor. [18F]FL2-b was synthesized in 1.0% radiochemical yield (nondecay corrected, n = 3), >99% radiochemical purity, from a 6-chloro pyridine precursor. Autoradiography experiments with AD positive and healthy control brain samples were used to determine the specificity of binding for the radioligands compared to [11C]PiB, a known imaging agent for β-amyloid (Aβ) aggregates. The Kd for [11C]L2-b and [18F]FL2-b were found to be 3.5 and 9.4 nM, respectively, from those tissue studies. Displacement studies of [11C]L2-b and [18F]FL2-b with PiB and AV-45 determined that L2-b binds to Aβ aggregates differently from known radiopharmaceuticals. Finally, brain uptake of [11C]L2-b was examined through microPET imaging in healthy rhesus macaque, which revealed a maximum uptake at 2.5 min (peak SUV = 2.0) followed by rapid egress (n = 2).

N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression

Novel dual inhibitors of histone deacetylase (HDAC) and heat-shock protein 90 (HSP90) are synthesized and evaluated. These compounds are endowed with potent HDAC and HSP90 inhibitory activities with IC50 values in nanomolar range with Compound 20 (HDAC IC50 = 194 nM; HSP90α IC50 = 153 nM) and compound 26 (HDAC IC50 = 360 nM; HSP90α IC50 = 77 nM) displaying most potent HDAC and HSP90α inhibitory activities. Both of these compounds induce HSP70 expression and down regulate HSP90 client proteins which play important roles in the regulation of survival and invasiveness in cancer cells. In addition, compounds 20 and 26 induce acetylation of α-tubulin and histone H3. Significantly, compounds 20 and 26 could effectively reduce programmed death-ligand 1 (PD-L1) expression in IFN-γ treated lung H1975 cells in a dose dependent manner. These findings suggest that dual inhibition of HDAC and HSP90 that can modulate immunosuppressive ability of tumor area may provide a better therapeutic strategy for cancer treatment in the future.

Protein Kinase Conjugates and Inhibitors

The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kin